ERBB2 and breast cancer: Alternatively, the increasing use of preoperative therapy should provide a clinical research platform for the prediction of the response to combinations of anti-HER2 agents with cytotoxic chemotherapy to stratify patients for the following treatment(s) to improve therapeutic outcomes for patients with refractory HER2-positive BC.